Effect of once-weekly semaglutide on insulin use in subjects with type 2 diabetes: a post hoc analysis of SUSTAIN 6

被引：0
|
作者：
Seufert, J. [1 ]
Desouza, C. [2 ]
Kirk, A. R. [3 ]
Lawson, J. [3 ]
Lingvay, I. [4 ]
Sondergaard, A. L. [3 ]
Bain, S. C. [5 ]
机构：
[1] Univ Hosp Freiburg, Endocrinol Diabetol, Freiburg, Germany
[2] Univ Nebraska Med Ctr, Omaha, NE USA
[3] Novo Nordisk AS, Soborg, Denmark
[4] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[5] Swansea Univ, Med Sch, Swansea, W Glam, Wales
来源：
DIABETOLOGIA | 2021年 / 64卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
483
引用
收藏
页码：251 / 252
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of once-weekly semaglutide in elderly subjects with type 2 diabetes: post hoc analysis of SUSTAIN 1-5 trials
    Warren, M.
    Chaykin, L.
    Trachtenbarg, D.
    Nayak, G.
    Wijayasinghe, N.
    Cariou, B.
    [J]. DIABETOLOGIA, 2017, 60 : S378 - S379
  • [2] The effect of once-weekly semaglutide on MACE, blood pressure and lipids by race and ethnicity: a SUSTAIN 6 post hoc analysis
    Bain, S. C.
    Desouza, C. V.
    Gondolf, T.
    Hansen, T.
    Holst, I.
    Rea, R. R.
    Seufert, J.
    [J]. DIABETOLOGIA, 2019, 62 : S365 - S365
  • [3] Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
    Leiter, Lawrence A.
    Bain, Stephen C.
    Hramiak, Irene
    Jodar, Esteban
    Madsbad, Sten
    Gondolf, Theis
    Hansen, Thomas
    Holst, Ingrid
    Lingvay, Ildiko
    [J]. CARDIOVASCULAR DIABETOLOGY, 2019, 18 (1)
  • [4] Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
    Lawrence A. Leiter
    Stephen C. Bain
    Irene Hramiak
    Esteban Jódar
    Sten Madsbad
    Theis Gondolf
    Thomas Hansen
    Ingrid Holst
    Ildiko Lingvay
    [J]. Cardiovascular Diabetology, 18
  • [5] Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial
    Kobo, O.
    Cavender, M. A.
    Gylvin, S. Hinsch
    Kuhlman, A. B.
    Rasmussen, S.
    Verma, S.
    [J]. EUROPEAN HEART JOURNAL, 2023, 44
  • [6] Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China
    Ji, Linong
    Lu, Yibing
    Shen, Zewei
    Hu, Ping
    Liu, Wenyan
    Zhang, Qiu
    Shi, Bimin
    [J]. DIABETES OBESITY & METABOLISM, 2024,
  • [7] Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in insulin-naive subjects with type 2 diabetes (SUSTAIN 4)
    Aroda, Vanita
    Bain, Stephen
    Cariou, Bertrand
    Piletic, Milivoj
    Rose, Ludger
    Bergan, Eirik Quamme
    Zacho, Jeppe
    Devries, J. Hans
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S51 - S51
  • [8] Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naive subjects with type 2 diabetes (SUSTAIN 4)
    DeVries, J. H.
    Bain, S. C.
    Cariou, B.
    Rose, L.
    Axelsen, M.
    Rowe, E.
    Aroda, V. R.
    [J]. DIABETOLOGIA, 2016, 59 : S76 - S77
  • [9] Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naive subjects with Type 2 diabetes (SUSTAIN 4)
    Aroda, V. R.
    Bain, S. C.
    Cariou, B.
    Piletic, M.
    Rose, L.
    Axelsen, M.
    Rowe, E.
    de Vries, J. H.
    [J]. DIABETIC MEDICINE, 2017, 34 : 146 - 146
  • [10] Efficacy and safety of once-weekly semaglutide monotherapy vs placebo in subjects with Type 2 diabetes (SUSTAIN 1)
    Sorli, C.
    Harashima, S-I
    Tsoukas, G.
    Unger, J.
    Karsbol, J. D.
    Bain, S.
    [J]. DIABETIC MEDICINE, 2017, 34 : 145 - 145
12345